Anavex Life Sciences Reports Reduced Operating Expenses and Increased Cash Reserves for December 2025 Quarter

Anavex Life Sciences Corp. reported its financial results for the three months ending December 31, 2025, revealing a significant reduction in operating expenses and a notable increase in cash reserves. The company recorded total operating expenses of $6.8 million, down from $13.6 million in the same period last year. This decrease was primarily driven by reduced research and development costs, which fell to $4.7 million from $10.4 million, attributed to the completion of various clinical trials and manufacturing activities related to its lead compound, ANAVEX®2-73. The net loss for the quarter was $5.7 million, or $0.06 per share, compared to a net loss of $12.1 million, or $0.14 per share, in the prior year.

In terms of liquidity, Anavex reported cash and cash equivalents of $131.7 million as of December 31, 2025, an increase from $102.6 million at the end of the previous quarter. This increase was largely due to the issuance of 6,003,237 shares under the 2025 Sales Agreement, generating net proceeds of $36.3 million. The company’s working capital also improved to $126.6 million, up from $94.9 million, reflecting a stronger financial position to support ongoing clinical trials and operational needs.

Operationally, Anavex continues to focus on its clinical pipeline, which includes ANAVEX®2-73 for Alzheimer’s disease, Parkinson’s disease, and Rett syndrome, as well as ANAVEX®3-71 for schizophrenia and frontotemporal dementia. The company is advancing its clinical trials, with ANAVEX®2-73 currently undergoing a re-examination process by the European Medicines Agency (EMA) following a negative trend vote on its Marketing Authorization Application. The company has requested a consultation with a Scientific Advisory Group to support its case.

Anavex's strategic developments include the ongoing evaluation of genomic data to identify biomarkers that may enhance the efficacy of its treatments. The company is also exploring additional indications for its compounds, including potential applications in other neurodegenerative and neurodevelopmental diseases. Looking ahead, Anavex remains focused on advancing its clinical programs while managing its cash resources prudently to navigate the complexities of drug development in a highly competitive market.